US Court Offers Second Chance On GSK-Teva ‘Skinny Label’ Ruling
Controversial Appeals Court Decision On Carve-Outs To Be Re-Examined
A controversial ruling that threatens so-called “skinny label” carve-outs of patented indications by US generics will be re-examined by the Court of Appeals for the Federal Circuit, following a petition by Teva.
